Moderna (NASDAQ:MRNA) President Sells $2,581,462.40 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $48.40, for a total value of $2,581,462.40. Following the completion of the transaction, the president owned 1,477,997 shares in the company, valued at $71,535,054.80. This trade represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Monday, February 23rd, Stephen Hoge sold 160,009 shares of Moderna stock. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56.

Moderna Stock Performance

Shares of MRNA stock opened at $48.12 on Thursday. The stock has a market capitalization of $19.09 billion, a PE ratio of -5.90 and a beta of 1.05. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55. The stock’s 50-day moving average price is $51.16 and its 200 day moving average price is $41.41. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s revenue was up 260.2% on a year-over-year basis. During the same quarter last year, the firm earned ($2.52) EPS. As a group, equities research analysts forecast that Moderna, Inc. will post -6.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRNA. Royal Bank Of Canada boosted their price target on Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research report on Monday, May 4th. Barclays boosted their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. The Goldman Sachs Group boosted their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Jefferies Financial Group set a $37.00 target price on Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Finally, UBS Group boosted their target price on Moderna from $36.00 to $45.00 and gave the stock a “neutral” rating in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $35.73.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently modified their holdings of the company. Canton Hathaway LLC acquired a new stake in shares of Moderna in the 1st quarter worth approximately $31,000. Assetmark Inc. grew its holdings in shares of Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the 2nd quarter worth approximately $28,000. Encore Global Management LP acquired a new stake in shares of Moderna in the 1st quarter worth approximately $51,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of Moderna in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.